INTRODUCTION
The incidence of cancer in transplant patients in the years following transplantation tends to increase due to the use of immunosuppressive agents. The risk of malignancy after transplantation is about 20% (1) . Although various cancers such as skin tumors, Kaposi's sarcoma and lymphoid malignancies have been reported in transplant recipients, gastric cancer is uncommon in these groups of patients (2) .
In Turkey, the number of liver transplantations from cadaver or living donors is increasing each year (3) . There are only a few studies about the risk of malignancies following liver transplantation (16) (17) (18) (19) . Herein, we report a case of gastric cancer occurring three years after cadaver-donated liver transplantation in a patient with autoimmune hepatitis.
CASE REPORT
A 51-year-old male was diagnosed to have chronic autoimmune hepatitis with positive anti-mitochondrial antibody, anti-LKM antibody and antinuclear antibodies (ANA) in 1993. Because of recurrent intractable variceal bleeding from the A variety of action mechanisms may account for cancer development after transplantation. Firstly, most of the cancers in this population are often associated with oncogenic viruses such as EpsteinBarr virus and herpes virus and/or with the immunosuppressive therapy used for transplantation (6). Epstein-Barr virus often causes lymphoproliferative disorders in transplant recipients, while human herpes virus 8 accounts for skin cancer and Kaposi's sarcoma (7) (8) (9) . However, the role of infectious agents is not clear for gastrointestinal cancer. Immunosuppressive treatment might predispose to Hp infection, which plays an important role in developing gastric cancer (10) . In this setting, Hp eradication treatment might be an important point in Hp-positive transplant recipients. Secondly, inhibition of T cell-induced immunity and suppression of interleukin (IL)-2 may take a role in carcinogenesis and tumor growth in patients receiving immunosuppressive treatment (11, 12) . Furthermore, many immunosuppressive drugs increase the risk of cancer after transplantation without known mechanisms. Long-term use of thiopurines in transplant patients has been shown to be associated with a significantly increased risk for various types of cancer (13) . Tacrolimus was also shown as an independent risk factor for malignancy in renal transplant patients (4). Benlloch et al. (18) reported an increase in the frequency of de novo malignancies after liver transplantation in recent years (before vs after 1995). The time interval between liver transplantation and diagnosis of de novo malignancy was shorter (58 vs 22 months, before and after 1995, respectively) (18) . They hypothesized that these findings were attributable to immunosuppression in association with the recent introduction of novel and potent immunosuppressive drugs. Thus, lowering the dose of immunosuppressive drugs or using new agents such as sirolimus and everolimus with anti-proliferative effect in immunosuppressive therapy after transplantation might help in reducing the risk of posttransplant malignancy.
To date, fewer than 10 cases of gastric cancer after liver transplantation have been published (14, (15) (16) (17) (18) (19) . In these cases, patients generally had received living donor liver transplants in contrast to the present case, who received a cadaveric liver transplant for liver failure due to autoimmune hepatitis. Immunologic stimulation in autoimmune diseases may promote carcinogenesis, i.e. some autoimmune diseases such as systemic lupus and rheumatoid arthritis are associated with lymphoproliferative malignancies but not with gastric cancer. However, no data exist about the risk of cancer in transplant patients with a history of an autoimmune disease.
The prognosis of patients with post-transplant tumors is worse than in the normal population, and systemic treatment options are limited in this group because of their immunocompromised status. Therefore, early detection and treatment of malignant diseases might be more crucial in transplant patients. Patients with increased risk deserve more aggressive investigation and meticulous therapy, because of the considerably high cancer mortality rate after liver transplantation. There is no standard screening procedure for solid tumors described for transplant patients. Transplant patients with gastric symptoms should be carefully evaluated, and endoscopic evaluation should be considered for early diagnosis.
In conclusion, with the increasing population and surveillance, malignancies are forthcoming health problems in transplant patients. In these patients, early diagnosis of malignancy after transplantation is very important because of the toxicity of chemotherapy agents and the increased risk of morbidity and mortality. A higher attention should be taken with respect to post-transplant patients with a history of autoimmune disease. Although gastric cancer is one of the infrequent tumors in transplanted patients, physicians should be aware of the risk.
